Hey mate, I wouldn't be looking at running whilst we have just learnt to walk. Need to actually turn a profit, then their dividend policy can kick in. That's if they aren't acquiring for further growth. (Not going to read the constitution, but prob in there somewhere, typically 40-60%)
Company is still burning too much $!! We need to increase the $10m saved and also ensure our revenue is rising without significant uptick in costs.
Can see why the share price didn't maintain the SEP/Oct gains. Nextstellis was flat, and we can't afford it to be. Awesome to finally see MYX make fast calls to address. And the Jan rise (10%) was needed, and if it can be maintained, there is significant upside (refer Hadrian's projections
). There are a couple of Derm products which have scope to increase sales, TxD not a huge amount because of the nature of the drugs. The biggest contributor to the company valuation will be Nextstellis for some time!!
There are definitely some interesting aspects to the financial report. Commentary that underlying EBITDA is $8m, but excluding the $20m odd that was used to increase revenue WTF?
Also good to see a restating of the Nextstellis goodwill, except the patent extension was used to extend the lifespan significantly, therefore reducing the write-down. Fingers crossed there are no 'new' entries in the next 15 years haha.
Hopefully some joy to the longterm holders like myself (I've been able to average down, which is nice). Some way to go, but we have seen an MYX which has well and truely broken the shackles of the *horrible* previous management.
GLTA
(20min delay)